Hundreds of new Xarelto side effects cases are being filed each month in Philadelphia’s Complex Litigation Center, where more than 1,700 cases are pending, and plaintiffs attorneys don’t appear to be slowing the trend.
As many as 400 to 600 new cases are being filed each month by patients who blame Johnson & Johnson’s Janssen Pharmaceuticals and Bayer for not adequately warning about serious bleeding risks with their blood thinner Xarelto. Plaintiffs also claim that the drug companies also didn’t inform doctors to monitor patients to reduce their risk for life-threatening bleeds, including gastrointestinal bleeds and brain hemorrhages.
Plaintiffs attorneys are fine-tuning their argument to change the trend of recent victories for the defense in the massive Xarelto multidistrict litigation, where more than 18,000 cases are pending. The first Philadelphia case to go to trial resulted in a $28 million verdict for the plaintiff, but Judge Michael Erdos reversed the verdict.
Xarelto is used to prevent strokes in patients with atrial fibrillation, to treat and prevent deep vein thrombosis and pulmonary embolism, and to prevent blood clots in patients who have recently undergone hip or knee replacement surgery. Like all blood thinners, Xarelto carries a risk for serious bleeding events.
Xarelto was approved by the Food and Drug Administration (FDA) in 2011, but it wasn’t until last month that an antidote was approved to reverse the blood thinning effects of Xarelto in the event of a bleeding emergency.